This week at AAN in Los Angeles, I had the opportunity to speak with Dr Jens Kuhle about a hot topic, neurofilaments in multiple sclerosis and other neurodegenerative diseases. Dr…
read moreBiogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients. You can find the original press…
read moreTwo recent studies have prompted the American Heart Association (AHA) to change their guidelines on early stroke management, extending the window of emergency stroke treatment up to 24 hours. Two randomized…
read moreWe have talked to Dr Paolo Ripellino from the Ospedale Civico di Lugano (EOC), Switzerland, about his research on neurological complications related to hepatitis E infection. Dr Ripellino has recently…
read moreExperts are enthusiastic about a new shingles vaccine that received FDA approval last month. Shingrix is significantly more effective than the only currently available shingles vaccine and provides considerably longer…
read moreI had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the long-term treatment effect of teriflunomide…
read moreAt ECTRIMS-ACTRIMS in Paris, France, I had the chance to sit down with Dr Patricia Mulero to discuss FLOODLIGHT: a prospective pilot study that has been exploring the feasibility of…
read moreChildren and adolescents living with MS face physical and cognitive disability that can severely limit their ability to perform daily activities, such as attending school. During the recent ECTRIMS-ACTRIMS meeting…
read moreAn update on pregnancy outcomes following ocrelizumab (OCR) treatment in patients with multiple sclerosis (MS) and other autoimmune diseases was delivered at this year’s joint ECTRIMS-ACTRIMS meeting, held 25-28 October…
read moreFriday’s programme at the ECTRIMS-ACTRIMS meeting in Paris played host to an exploration of pregnancy outcomes in multiple sclerosis (MS) patients treated with teriflunomide – a once-daily oral immunomodulator approved…
read more
